Tags

Type your tag names separated by a space and hit enter

Evidence-based medicine in migraine prevention.
Expert Rev Neurother. 2005 May; 5(3):333-41.ER

Abstract

Migraine headache is a chronic, painful, disabling and potentially progressive, condition primarily occurring in early and middle adulthood. For many patients, daily activities are impaired by the sudden and unpredictable occurrence of migraine attacks. In recent years, significant progress has been made in the field of migraine treatment. For the acute treatment of migraine attacks, 5-hydroxytryptophan(1B/D) agonists (so called triptans), were the most innovative development, successfully aborting attacks in less than 1 h. The search for innovative drugs usable for migraine prevention, however, was less successful, mainly due to the lack of reliable and predictive animal models. Recently, neuromodulators such as valproic acid and topiramate, initially developed as anticonvulsants, have been shown in large clinical trials to be effective in the prevention of migraine. As for the acute treatment of migraine attacks more than 10 years ago, large clinical trial programs are now setting new standards for evidence-based medicine in migraine prevention. This review summarizes the current options in migraine prevention with special emphasis on clinical trial design and new developments such as topiramate.

Authors+Show Affiliations

University Hospital Essen, Department of Neurology, Hufelandstrasse 55, 45122 Essen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15938666

Citation

Yoon, Min-Suk, et al. "Evidence-based Medicine in Migraine Prevention." Expert Review of Neurotherapeutics, vol. 5, no. 3, 2005, pp. 333-41.
Yoon MS, Savidou I, Diener HC, et al. Evidence-based medicine in migraine prevention. Expert Rev Neurother. 2005;5(3):333-41.
Yoon, M. S., Savidou, I., Diener, H. C., & Limmroth, V. (2005). Evidence-based medicine in migraine prevention. Expert Review of Neurotherapeutics, 5(3), 333-41.
Yoon MS, et al. Evidence-based Medicine in Migraine Prevention. Expert Rev Neurother. 2005;5(3):333-41. PubMed PMID: 15938666.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evidence-based medicine in migraine prevention. AU - Yoon,Min-Suk, AU - Savidou,Irini, AU - Diener,Hans-Christoph, AU - Limmroth,Volker, PY - 2005/6/9/pubmed PY - 2006/6/6/medline PY - 2005/6/9/entrez SP - 333 EP - 41 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 5 IS - 3 N2 - Migraine headache is a chronic, painful, disabling and potentially progressive, condition primarily occurring in early and middle adulthood. For many patients, daily activities are impaired by the sudden and unpredictable occurrence of migraine attacks. In recent years, significant progress has been made in the field of migraine treatment. For the acute treatment of migraine attacks, 5-hydroxytryptophan(1B/D) agonists (so called triptans), were the most innovative development, successfully aborting attacks in less than 1 h. The search for innovative drugs usable for migraine prevention, however, was less successful, mainly due to the lack of reliable and predictive animal models. Recently, neuromodulators such as valproic acid and topiramate, initially developed as anticonvulsants, have been shown in large clinical trials to be effective in the prevention of migraine. As for the acute treatment of migraine attacks more than 10 years ago, large clinical trial programs are now setting new standards for evidence-based medicine in migraine prevention. This review summarizes the current options in migraine prevention with special emphasis on clinical trial design and new developments such as topiramate. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/15938666/Evidence_based_medicine_in_migraine_prevention_ L2 - http://www.tandfonline.com/doi/full/10.1586/14737175.5.3.333 DB - PRIME DP - Unbound Medicine ER -